ACP
CDTX

Aveo Capital Partners’s Cidara Therapeutics CDTX Stock Holding History

Aveo Capital Partners’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,125
Closed -$17.9K – 366
2023
Q4 		$17.9K Sell
1,125
-1,000
-47% -$16.1K ﹤0.01% 338
2023
Q3 		$40K Hold
2,125
– – 0.01% 330
2023
Q2 		$48K Hold
2,125
– – 0.01% 332
2023
Q1 		$54K Hold
2,125
– – 0.01% 332
2022
Q4 		$32.1K Hold
2,125
– – ﹤0.01% 327
2022
Q3 		$27K Hold
2,125
– – ﹤0.01% 270
2022
Q2 		$21K Hold
2,125
– – ﹤0.01% 268
2022
Q1 		$35K Hold
2,125
– – 0.01% 273
2021
Q4 		$54K Buy
2,125
+1,000
+89% +$31.1K 0.01% 282
2021
Q3 		$50K Buy
+1,125
New +$42.7K 0.01% 254

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Aveo Capital Partners's CDTX Position: Q1 2024 in Review

Aveo Capital Partners sold out of Cidara Therapeutics (CDTX) in Q1 2024, closing a stake of 1,125 shares — an estimated $17.9K sold.

Aveo Capital Partners first reported a position in CDTX in Q3 2021 and held it in 10 quarters. The position peaked at $54K in Q4 2021. 50 funds tracked by Wall St. Rank hold CDTX as of Q1 2024.

  • Aveo Capital Partners reported no remaining Cidara Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Aveo Capital Partners sold 1,125 Cidara Therapeutics shares in Q1 2024, an estimated $17.9K.
  • Aveo Capital Partners first reported a position in Cidara Therapeutics in Q3 2021 and held it in 10 quarters.
  • Aveo Capital Partners's Cidara Therapeutics position peaked at $54K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2024.

Based on Aveo Capital Partners's 13F filing for Q1 2024, filed 6 May 2024.